TEHR vs Beluga Health: Scope, Pricing and Migration

Where does Beluga sit in a brand’s existing stack?

Beluga’s platform page separates acquisition, commerce, clinical care and support. It offers direct API integration, a platform-partner route and commercial arrangements for operators building infrastructure for other brands. A customer can retain an existing commerce system or use hosted intake. This matters because a decision about Beluga may also require a decision about the software around it.

TEHR positions its technology and administrative infrastructure around a brand’s patient experience, connected to independent clinical services and pharmacy coordination. To compare the options, draw the actual stack proposed in each contract. Identify the patient portal, checkout, merchant account, subscription system, clinical record, pharmacy connection and support inbox. Name the party responsible for each component.

The right result is not necessarily the fewest logos on the diagram. An established operator may benefit from retaining a capable commerce team. A founder without that team may prefer a more consolidated experience. Start with what white-label telehealth includes before treating two differently scoped proposals as interchangeable.

How do the documented capabilities compare?

All competitor statements below are dated as of October 22, 2026 and reflect the cited public pages. “Not stated on reviewed pages” means an unanswered question, not an absent capability. TEHR’s column describes its service model; program-specific scope belongs in the proposal.

How should you evaluate clinical and fulfillment responsibilities?

Beluga describes a physician-led network covering all 50 states and DC, with pharmacy routing that can use customer-selected pharmacies, partner pharmacies or a combination. Its pharmacy and labs page also describes several collection methods. Those choices may be useful when a brand already has pharmacy contracts or wants a particular patient testing experience.

Ask how an actual treatment pathway works. Who decides that testing is required? Where does a result arrive? Who follows up on an abnormal finding? Which party explains a change in medication or a clinical denial? A broad catalog does not replace answers to those operational questions, and nationwide network reach does not make every program available everywhere.

TEHR’s clinical decisions similarly rest with independent licensed providers. The brand controls its commercial identity, not clinical judgment. Put the handoffs into the platform demonstration, including a declined request, a lab-dependent visit and a prescription that cannot be routed to the first pharmacy.

What does a fair cost comparison include?

Beluga explicitly says it takes no cut of customer revenue. Its pricing page describes flat monthly access, per-visit charges and pharmacy/lab pass-through, with separately disclosed coordination charges and volume tiers. It also describes an integration fee credited against future visits. Actual dollar rates are quoted during scoping.

TEHR’s stated model is a flat platform subscription plus a flat transaction fee and 0% revenue share, with actual amounts provided in a scoped quote. Therefore, no revenue share is common ground, not an exclusive TEHR differentiator. The more useful comparison is what a transaction means, what a visit means, when each is billed, and what work the brand still performs.

Request sample invoices for the same hypothetical month, including repeat patients, synchronous visits, cancellations and fulfillment exceptions. Keep pharmacy costs and clinical costs separate from software fees. Then use TEHR pricing to resolve scope differences. A flat access fee may be predictable while usage and third-party costs still move materially with the program mix.

What changes when existing patients need to move?

Beluga’s switching page describes discovery, parallel integration and gradual traffic movement, with a headline estimate of four to six weeks. That is evidence that Beluga supports migrations into its own service. It does not establish the export terms, data fields or offboarding commitments available when moving away from it.

For a move to TEHR, identify which systems actually hold the information. Beluga may hold clinical records while a separate platform holds subscriptions and a processor holds payment credentials. Each owner needs a transfer plan. Request exports early, match identifiers across systems and agree on the last clinical encounter handled by the existing arrangement before new routing begins.

The Beluga-to-TEHR migration guide should be read with the patient migration checklist. Use an agreed test group and reconcile active treatments before expanding. A migration is complete when the intended care and billing journeys work, not merely when a spreadsheet imports.

How should you interpret launch timelines?

Beluga says its platform-partner path is its fastest route, while direct API work depends on the customer’s technical capacity. That distinction should shape procurement. A developer-led operator can ask for sample payloads and exception events; a nontechnical brand should ask who will configure and maintain the patient-facing experience.

TEHR should be evaluated against the route you would actually buy. Compare a complete TEHR implementation with Beluga plus the necessary platform and operating partners, or compare narrower integrations on both sides. Do not compare a clinical connection date with a fully configured brand launch.

Before setting a public launch date, test intake completion, identity handling, clinical escalation, pharmacy status, support messaging and subscription changes. Ask who remains available after go-live to resolve an integration problem that spans more than one company.

When should you choose TEHR or Beluga Health?

Choose TEHR for further evaluation if you want its operator-led brand infrastructure, prefer the proposed division of support and administrative work, and find the written economics attractive for your actual programs. Its founders’ experience running brands can inform implementation questions, but the project still needs measurable acceptance criteria.

Choose Beluga for further evaluation if you want a modular physician-led clinical layer while retaining your merchant account, commerce stack or pharmacy relationships. Its public pages make that architecture explicit. The ability to preserve working systems can be a benefit, provided your team can manage the boundaries between them.

For a wider shortlist, read Beluga Health alternatives. Decide whether the reason for changing vendors is clinical scope, integration effort, support ownership or economics. If that reason is unclear, changing the clinical backend alone may leave the underlying operating problem untouched.

What should you request before making the decision?

Ask for an itemized proposal, a responsibility map and a demonstration using your actual program requirements. Record unresolved questions with an owner and a due date. Review the resource library for related definitions and operating checklists, then bring the current workflow and intended changes to a scoped discussion. A useful agreement identifies what the vendor will deliver, what your team must supply, how exceptions are handled and what evidence will demonstrate readiness. It should also explain the practical exit process, so future changes do not depend on assumptions about records, subscriptions or access.

For a wider category view, compare the white-label telehealth platform shortlist and the turnkey telehealth platform shortlist. Use the first to examine brand and architecture choices, and the second to assess which implementation and operating tasks a proposed package actually supplies.

What else should you know?